TY - JOUR T1 - Environmental surveillance for <em>Salmonella</em> Typhi as a tool to estimate the incidence of typhoid fever in low-income populations JF - medRxiv DO - 10.1101/2021.05.21.21257547 SP - 2021.05.21.21257547 AU - Christopher B. Uzzell AU - Catherine M. Troman AU - Jonathan Rigby AU - Venkata Raghava Mohan AU - Jacob John AU - Dilip Abraham AU - Rajan Srinivasan AU - Satheesh Nair AU - John Scott Meschke AU - Nicola Elviss AU - Gagandeep Kang AU - Nicholas Feasey AU - Nicholas C. Grassly Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/22/2021.05.21.21257547.abstract N2 - Background The World Health Organisation recommends prioritised use of recently prequalified typhoid conjugate vaccines in countries with the highest incidence of typhoid fever. However, representative typhoid surveillance data are lacking in many low-income countries because of the costs and challenges of diagnostic clinical microbiology. Environmental surveillance (ES) of Salmonella Typhi in sewage and wastewater using molecular methods may offer a low-cost alternative, but its performance in comparison with clinical surveillance has not been assessed.Methodology/Principal Findings We developed a harmonised protocol for typhoid ES and its implementation in communities in India and Malawi where it will be compared with findings from hospital-based surveillance for typhoid fever. The protocol includes methods for ES site selection based on geospatial analysis, grab and trap sample collection at sewage and wastewater sites, and laboratory methods for sample processing, concentration and quantitative PCR to detect Salmonella Typhi. The optimal locations for ES sites based on digital elevation models and mapping of sewage and river networks are described for each community and their suitability confirmed through field investigation. We will compare the prevalence and abundance of Salmonella Typhi in ES samples collected each month over a 12-month period to the incidence of blood culture confirmed typhoid estimated from cases recorded at referral hospitals serving the study areas and community surveys of healthcare seeking for individuals with fever.Significance If environmental detection of Salmonella Typhi correlates with the incidence of typhoid fever estimated through clinical surveillance, typhoid ES may be a powerful and low-cost tool to estimate the local burden of typhoid fever and support the introduction of typhoid conjugate vaccines. Typhoid ES could also allow the impact of vaccination to be assessed and rapidly identify circulation of drug resistant strains.Author Summary Typhoid fever is a bacterial enteric infection that remains a significant health burden to the 6.4 billion people living in low- and middle-income countries. The WHO recently prequalified highly immunogenic typhoid conjugate vaccines (TCVs) and recommended that the introduction of public vaccination programmes should be based on an understanding of the local epidemiology of infection. However, representative data on the community level describing incidence of microbiologically confirmed typhoid cases are limited, reflecting the costs and challenges of implementing blood culture for Salmonella Typhi (S. Typhi). Therefore, cost-effective alternative means of community surveillance are required to assess overall burden of disease.We developed a protocol for typhoid environmental surveillance, including methods for the identification of suitable sampling sites, sample collection and laboratory processing. The detection of S. Typhi in wastewater and sewage samples will be examined against the outcomes of hospital-based surveillance for typhoid fever with healthcare utilisation surveys to evaluate and validate the use of ES as an effective means of assessing community level incidence of typhoid. The findings of this study will inform potential wider implementation of ES for typhoid to support the introduction of TCVs and monitor their impact.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The Bill &amp; Melinda Gates Foundation (https://www.gatesfoundation.org/; Grant No. INV-002381).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We report on a protocol for environmental surveillance for Salmonella typhi and present results of an environmental surveillance site selection process for this surveillance activity. The Imperial College London Research Ethics Committee (ICREC) has confirmed that ethical approval for the use of environmental surveillance samples is not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referenced to in this manuscript are fully available without restriction and available in the Supplementary Information documents. ER -